^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    iniparib (BSI 201)

    i
    Company:
    Sanofi
    Drug class:
    PARP1 inhibitor
    Related drugs:
    Apply
    Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients (SOLTI NEOPARP) (NCT01204125)
    Phase 2
    Sanofi
    Completed
    Last update posted :
    03/22/2017
    Initiation :
    09/01/2010
    Primary completion :
    10/01/2012
    Completion :
    02/01/2017
    HER-2 • ER • PGR
    |
    HER-2 overexpression
    |
    paclitaxel • iniparib (BSI 201)
    A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis (NCT01173497)
    Phase 2
    Sanofi
    Completed
    Last update posted :
    03/17/2016
    Initiation :
    07/01/2010
    Primary completion :
    10/01/2012
    Completion :
    07/01/2013
    HER-2 • ER • PGR
    |
    HER-2 negative • ER negative • PGR negative
    |
    irinotecan • iniparib (BSI 201)
    A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer (NCT00813956)
    Phase 2
    Sanofi
    Completed
    Last update posted :
    03/17/2016
    Initiation :
    12/01/2008
    Primary completion :
    10/01/2012
    Completion :
    10/01/2012
    HER-2 • PGR
    |
    HER-2 negative
    |
    carboplatin • gemcitabine • iniparib (BSI 201)